These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28944433)

  • 21. [Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
    Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui RZ
    Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2195-9. PubMed ID: 24169327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LDL and HDL subfractions, dysfunctional HDL: treatment options.
    Garcia-Rios A; Nikolic D; Perez-Martinez P; Lopez-Miranda J; Rizzo M; Hoogeveen RC
    Curr Pharm Des; 2014; 20(40):6249-55. PubMed ID: 24953394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
    Carlquist JF; Muhlestein JB; Horne BD; Hart NI; Bair TL; Molhuizen HO; Anderson JL
    Am Heart J; 2003 Dec; 146(6):1007-14. PubMed ID: 14660992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism.
    Rader DJ
    Am J Cardiol; 2003 Apr; 91(7A):18E-23E. PubMed ID: 12679199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomics of statin response.
    Mangravite LM; Wilke RA; Zhang J; Krauss RM
    Curr Opin Mol Ther; 2008 Dec; 10(6):555-61. PubMed ID: 19051133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes.
    Turner T; Stein EA
    Clin Ther; 2015 Dec; 37(12):2751-69. PubMed ID: 26548322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
    Serban MC; Banach M; Mikhailidis DP
    Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
    Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
    J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.